Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

55.14USD
22 Jun 2018
Change (% chg)

$1.20 (+2.22%)
Prev Close
$53.94
Open
$54.50
Day's High
$55.33
Day's Low
$54.24
Volume
3,472,609
Avg. Vol
2,109,781
52-wk High
$70.04
52-wk Low
$49.97

Select another date:

Mon, Jun 4 2018

Mixed results for Bristol/Nektar combination in cancer trial

Chicago, June 3 Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

BRIEF-Omega Advisors Takes Share Stake In UnitedHealth, Bristol-Myers Squibb

* OMEGA ADVISORS DISSOLVES SHARE STAKE IN AMERICAN AIRLINES - SEC FILING

BRIEF-Bristol-Myers Squibb Elects Each Of Company's 12 Nominees To Serve As Directors

* BRISTOL-MYERS SQUIBB CO - SHAREHOLDERS ELECTED EACH OF COMPANY'S 12 NOMINEES TO SERVE AS DIRECTORS OF COMPANY UNTIL 2019 ANNUAL MEETING

BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB'S TYPE II VARIATION APPLICATION FOR OPDIVO PLUS YERVOY COMBINATION FOR TREATMENT OF FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

* BRISTOL-MYERS SQUIBB AND FLATIRON HEALTH EXPAND COLLABORATION WITH A THREE-YEAR AGREEMENT

BRIEF-Advantagene Announces Clinical Trial Collaboration

* ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB

Bristol-Myers raises 2018 forecast, some sales disappoint

NEW YORK Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down almost 1 percent.

UPDATE 3-Bristol-Myers raises 2018 forecast, some sales disappoint

NEW YORK, April 26 Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down almost 1 percent.

BRIEF-CEO Says Bristol-Myers Still A Growth Company

* BRISTOL-MYERS SQUIBB SEES CONTINUED GROWTH IN ANTICOAGULANT MARKET SHARE FOR ELIQUIS

Bristol-Myers profit tops Street view, raises 2018 forecast

NEW YORK, April 26 Bristol-Myers Squibb Co on Thursday reported a first-quarter profit that exceeded Wall Street estimates on strong demand for its two most important medicines, and the U.S. drugmaker raised its full-year earnings forecast.

Select another date: